Tag: Beyfortus
-
Bronchiolitis and Beyfortus: Expanded indication for vulnerable children up to 24 months
Overview: Beyfortus and the fight against RSV bronchiolitis Bronchiolitis is a common respiratory illness in young children, most notably caused by the respiratory syncytial virus (RSV). Protecting vulnerable infants and toddlers from severe RSV infections has long been a priority for pediatric care teams. Beyfortus, the synthetic antibody nirsevimab developed by AstraZeneca and marketed by…
-
Beyfortus Expanded: RSV Prophylaxis Up to 24 Months for Vulnerable Children
Overview of Beyfortus’ Expanded indication The Beyfortus (nirsevimab) monoclonal antibody, originally approved to protect infants against severe RSV infection, has had its indication widened. Regulators have approved its use in children up to 24 months who remain vulnerable to a severe RSV illness. This development extends access to a passive immunization approach that can help…